1. Home
  2. ASGN vs DMRA Comparison

ASGN vs DMRA Comparison

Compare ASGN & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ASGN Incorporated

ASGN

ASGN Incorporated

BUY

Current Price

$19.79

Market Cap

1.8B

ML Signal

BUY

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$20.94

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASGN
DMRA
Founded
1985
2011
Country
United States
United States
Employees
N/A
7
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
ASGN
DMRA
Price
$19.79
$20.94
Analyst Decision
Sell
Buy
Analyst Count
7
2
Target Price
$38.43
$43.00
AVG Volume (30 Days)
9.7M
308.6K
Earning Date
04-22-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.13
N/A
Revenue
$3,980,400,000.00
N/A
Revenue This Year
$3.26
N/A
Revenue Next Year
$4.94
N/A
P/E Ratio
$150.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.31
$16.50
52 Week High
$60.06
$28.76

Technical Indicators

Market Signals
Indicator
ASGN
DMRA
Relative Strength Index (RSI) 18.34 36.58
Support Level N/A N/A
Resistance Level $47.94 $27.70
Average True Range (ATR) 1.84 1.91
MACD -0.85 -0.31
Stochastic Oscillator 1.21 29.72

Price Performance

Historical Comparison
ASGN
DMRA

About ASGN ASGN Incorporated

ASGN Inc is a provider of information technology (IT) services and professional solutions, including technology, creative, and digital, across the commercial and government sectors. It operates through two segments, Commercial and Federal Government. The Commercial Segment, which generates the majority of the revenue, provides consulting, creative digital marketing, and permanent placement services to Fortune 1000 clients and mid-market companies. The Federal Government Segment provides mission-critical solutions to the Department of Defense, intelligence agencies, and civilian agencies.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: